Marcelo Pasquini is an Oncology physician affiliated with Cleveland Clinic. OpenAlex indexes 598 publications with 25,419 citations (h-index 73); ClinicalTrials.gov lists 2 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
9500 Euclid Ave
Cleveland, OH 441953522
Telephone
866-320-4573Provider last certified this registry record 12 Aug 2025.
Clinical trials
- Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma
Sponsor: Medical College of Wisconsin
- Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma
Sponsor: Center for International Blood and Marrow Transplant Research
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year20255 payments
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- National Marrow Donor ProgramProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
64.5%Kinase inhibitor64.5%Jakafi100%Part D<11 patientsDermatology
35.5%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor35.5%Acyclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma
New England Journal of Medicine
2022 - Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States
Biology of Blood and Marrow Transplantation
2022 - Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD
Journal of Clinical Oncology
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Samir Kapadia, MD
Cleveland Clinic
Lars Svensson, MD
Cleveland Clinic
Mina Chung, MD
Cleveland Clinic
Gene Barnett, MD
Cleveland Clinic
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”